For persistent pulmonary hypertension of the newborn (PPHN), therapies beyond sildenafil include inhaled nitric oxide (iNO), which directly relaxes pulmonary vasculature. iNO offers a rapid onset but carries risks of methemoglobinemia and requires specialized equipment.
Another option is prostacyclin analogs, such as epoprostenol, which also dilate pulmonary vessels. However, these necessitate continuous intravenous infusion and carry a risk of systemic effects.
Research actively explores alternative therapies, focusing on targeted gene therapies to address the underlying genetic causes of PPHN in certain cases. This approach holds the potential for long-term solutions, reducing reliance on systemic medications with their associated side effects.
Studies are also investigating improved drug delivery systems, aiming for better targeting and reduced systemic exposure to minimize side effects. Nanoparticle-based drug delivery is one promising avenue.
Further research should prioritize understanding individual patient responses to different treatments. This personalized approach could significantly improve treatment outcomes by tailoring therapies based on genetic predisposition, disease severity, and individual patient characteristics.
